Form 4: MiNK Therapeutics Director Peter Behner Acquires Shares in Lieu of Cash Compensation

Director Peter Behner acquired 18,753 shares of MiNK Therapeutics common stock at $0.82 per share in lieu of cash retainers for board and committee compensation.

Summary

• Peter Behner, a director of MiNK Therapeutics, acquired 18,753 shares of common stock on September 3, 2024.
• The shares were acquired at a price of $0.82 per share.
• The acquisition was made in lieu of cash retainers for board and committee compensation.
• Following the transaction, Behner directly owns 109,234 shares of MiNK Therapeutics.
• Behner also received restricted stock units (RSUs) that will vest one month from the grant date, each representing a contingent right to receive one share of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. A director taking shares in lieu of cash shows confidence and reduces cash outflow, but it's a routine transaction.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future.
• Using stock in lieu of cash preserves cash for the company.

Future Outlook

The RSUs will vest one month from the grant date.

Industry Context

This is a standard practice for compensating board members, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash and equity.
• Granting RSUs that vest over time is a common method to incentivize long-term commitment and performance.
• The specific amount and vesting schedule of RSUs can vary widely based on company size, industry, and individual contributions.

Stakeholder Impact

• Shareholders may view the director's stock acquisition positively, as it aligns their interests with management.
• The company benefits from preserving cash by issuing stock instead of cash compensation.

Key Dates